AU2003228667A1 - Nucleic acid mediated disruption of hiv fusogenic peptide interactions - Google Patents
Nucleic acid mediated disruption of hiv fusogenic peptide interactionsInfo
- Publication number
- AU2003228667A1 AU2003228667A1 AU2003228667A AU2003228667A AU2003228667A1 AU 2003228667 A1 AU2003228667 A1 AU 2003228667A1 AU 2003228667 A AU2003228667 A AU 2003228667A AU 2003228667 A AU2003228667 A AU 2003228667A AU 2003228667 A1 AU2003228667 A1 AU 2003228667A1
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- fusogenic peptide
- acid mediated
- peptide interactions
- mediated disruption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37472202P | 2002-04-22 | 2002-04-22 | |
US60/374,722 | 2002-04-23 | ||
US10/157,580 | 2002-05-29 | ||
US10/157,580 US20030124513A1 (en) | 2001-05-29 | 2002-05-29 | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV |
US38678202P | 2002-06-06 | 2002-06-06 | |
US60/386,782 | 2002-06-06 | ||
US39803602P | 2002-07-23 | 2002-07-23 | |
US60/398,036 | 2002-07-23 | ||
US10/225,023 | 2002-08-21 | ||
US10/225,023 US20030175950A1 (en) | 2001-05-29 | 2002-08-21 | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
US40678402P | 2002-08-29 | 2002-08-29 | |
US60/406,784 | 2002-08-29 | ||
US40837802P | 2002-09-05 | 2002-09-05 | |
US60/408,378 | 2002-09-05 | ||
US40929302P | 2002-09-09 | 2002-09-09 | |
US60/409,293 | 2002-09-09 | ||
US44012903P | 2003-01-15 | 2003-01-15 | |
US60/440,129 | 2003-01-15 | ||
PCT/US2003/005190 WO2003070193A2 (en) | 2002-02-20 | 2003-02-20 | RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
AUPCT/US2003/005190 | 2003-02-20 | ||
PCT/US2003/012626 WO2003102131A2 (en) | 2002-04-22 | 2003-04-22 | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003228667A1 true AU2003228667A1 (en) | 2003-12-19 |
Family
ID=32046225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003228667A Abandoned AU2003228667A1 (en) | 2002-04-22 | 2003-04-22 | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003228667A1 (en) |
WO (1) | WO2003102131A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0226374D0 (en) * | 2002-11-12 | 2002-12-18 | Isis Innovation | Ligands |
US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
EP2397148A3 (en) * | 2006-02-02 | 2012-04-25 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
CN106086075B (en) * | 2016-06-23 | 2019-08-06 | 福建医科大学 | The construction method of CXCR4RNAi slow virus carrier |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08501928A (en) * | 1992-07-02 | 1996-03-05 | ハイブライドン インコーポレイテッド | Self-stabilizing oligonucleotides as therapeutic agents |
GB9827152D0 (en) * | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
DE19956568A1 (en) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
-
2003
- 2003-04-22 AU AU2003228667A patent/AU2003228667A1/en not_active Abandoned
- 2003-04-22 WO PCT/US2003/012626 patent/WO2003102131A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003102131A3 (en) | 2004-04-01 |
WO2003102131A2 (en) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002367466A1 (en) | Amplification of nucleic acid fragments using nicking agents | |
AU2003259155A1 (en) | Pharmaceutical compositions comprising hepatitis c viral protease inhibitors | |
AU2003248872A1 (en) | Hiv integrase inhibitors | |
AU2002257076A1 (en) | Nucleic acid shuffling | |
AU2003286535A1 (en) | Methods of manipulating nucleic acids | |
AU2002313683A1 (en) | Nucleic acid amplification using nicking agents | |
AU2002325538A1 (en) | Nucleic acid amplification methods | |
AU2002337419A1 (en) | Sublingual pharmaceutical formulation of desmopressin | |
AU2003252591A1 (en) | Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same | |
AU2002360820A1 (en) | Compositions for dna mediated gene silencing | |
AU2003280603A1 (en) | Method of amplifying nucleic acid | |
AU2003228667A1 (en) | Nucleic acid mediated disruption of hiv fusogenic peptide interactions | |
AU2003220249A1 (en) | Improved nucleic acid amplification | |
AU2003273608A1 (en) | Viral envelope mediated fusion assay | |
AUPS076802A0 (en) | Selective nucleic acid amplification | |
AU2002256280A1 (en) | Rapid and enzymeless cloning of nucleic acid fragments | |
AU2003282498A1 (en) | Hiv vaccine formulations | |
AU2003301850A1 (en) | Hiv vaccine | |
AU2003230070A1 (en) | Isolating nucleic acid | |
AU2003279509A1 (en) | Targeted double stranded rna mediated cell killing | |
AU2002223666A1 (en) | Use of enzymes obtained from ciliates as medicaments for promoting digestion | |
AU2003205817A1 (en) | Methods of nucleic acid amplification | |
AU2002362312A1 (en) | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof | |
AU2003252983A1 (en) | Amplification of nucleic acids | |
AU2002366435A1 (en) | Nucleic acid amplification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |